Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Daiichi Objects Sale...

    Daiichi Objects Sale of Religare to Religare Health Insurance, moves to Court

    Written by savita thakur thakur Published On 2017-04-18T15:11:13+05:30  |  Updated On 18 April 2017 3:11 PM IST
    Daiichi Objects Sale of Religare to Religare Health Insurance, moves to Court

    NEW DELHI: Japanese firm Daiichi Sankyo has again knocked the Delhi High Court's door over the sale of Religare Enterprises to Religare Health Insurance.


    The Japanese firm objected that the former Ranbaxy owners's Malvinder Singh and Shivinder Singh are liable to follow the Court's instructions as earlier the apex Court had directed the Singh brother to do not sale any of their stakes without the permission of Court.


    Read Also: Religare to sell Religare Health Insurance to PE fund Rs 1,040 cr


    Medical Dialogues team had earlier reported that Japanese Company Daiichi Sankyo filed an application in the Court in order to block the former Ranbaxy owners Malvinder and Shivinder Singh’s to sell any of their stakes in Fortis Healthcare and allied subsidiaries. Reacting over the Daiichi's application the court directed the two brother to seek the permission of the Delhi High Court before to sale of their assets.


    Read also: Do Not Sell any assets without Permission: Delhi HC to Singh Brothers


    Meanwhile, the Singh brothers said that court orders are not applicable to Religare as it is not party to the Japanese drug maker’s case to recover Rs 3,500 crore from them as part of an arbitration award.


    Supporting Daiichi's appeal, Daiichi counsel CA Sundaram alleged the brothers disobeyed the Court's order by moving ahead with Religare Enterprises’ stake sale.


    Speaking with BS, a spokesperson of RHC Holding Private Limited said, “We have complied with all the orders of the Hon’ble Court. The order is applicable only in respect to the unencumbered assets to parties to the litigation, namely RHC Holding and Oscar Investments. The operating listed entities of the group, including Religare, are not party to the litigation."


    “There is no order on any of the operating companies of the group, including Religare, which continues to run their businesses in normal course as separate listed entities. Daiichi Sankyo is moving applications only to delay hearing of the main matter and to prejudice the facts,” the spokesperson told ET.


    Medical Dialogues team had earlier reported that Daiichi Sankyo in its last hearing requested the court to include a third party auditor to inspect the financial details disclosed by former owners of Ranbaxy.


    Daiichi stated in its application that the third party auditor will also inspect the other 17 respondents and their shareholding in such unencumbered asset’s case along with the details disclosed in sealed covers by Malvinder and Shivinder Singh.


    Read also: Daiichi versus Singh Brothers: Daiichi Sankyo demands third party Audit


    arbitration caseDaiichi SankyoMalvinder Singh and Shivinder SinghReligareReligare EnterprisesReligare Health InsuranceSingh brothers
    Source : With inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok